<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45326">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044926</url>
  </required_header>
  <id_info>
    <org_study_id>S2013-1472-0002</org_study_id>
    <nct_id>NCT02044926</nct_id>
  </id_info>
  <brief_title>Intraductal Papillary Mucinous Neoplasm With Malignant Change</brief_title>
  <official_title>Intraductal Papillary Mucinous Neoplasm (IPMN) With Malignant Change: Prospective Study to Assess Diagnostic Performance of CT and Magnetic Resonance Imaging (MR) According to International Consensus Guidelines 2012</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      To investigate diagnostic performance of CT and MR in intraductal papillary mucinous
      neoplasm with malignant change according to international consensus guidelines 2012.

      Hypothesis: According to 2012 consensus guidelines, enhanced solid component and main
      pancreatic duct size of larger than 10 mm will be significant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose

             -  To investigate diagnostic performance of CT and MR in intraductal papillary
                mucinous neoplasm with malignant change according to international consensus
                guidelines 2012

        2. Enroll criteria

             -  Patient who is suspected to have pancreas IPMN on imaging

             -  Interval between imaging study and surgery is less than 2 months

             -  Who is scheduled for surgery due to IPMN
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>CT and MRI findings of patients who is scheduled for surgery</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will assess baseline CT and MRI findings of patients who is scheduled for surgery according to 2012 consensus guidelines.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">93</enrollment>
  <condition>IPMN</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patents who are suspected to have pancreas IPMN by clinicians or imaging studies
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who is suspected to have IPMN by imaging study or clinician

          -  Time interval between imaging study and surgery less than 2 months

        Exclusion Criteria:

          -  Patients who have pathology results not by surgery

          -  Who is less than 20 years old

          -  Who cannot voluntarily agree study design
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Ho Byun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae Ho Byun, Professor</last_name>
    <phone>82-10-8727-4284</phone>
    <email>jhbyun@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Ho Byun, Professor</last_name>
      <phone>82-10-8727-4284</phone>
      <email>jhbyun@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jae Ho Byun</investigator_full_name>
    <investigator_title>Jae Ho Byun</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
